Skip to content

Randomized Double-blinded Control Trial: Inhaled Budesonide as an Added-on Therapy in Acute Asthmatic Attack Children

Randomized Double-blinded Control Trial: Inhaled Budesonide as an Added-on Therapy in Acute Asthmatic Attack Children

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20190226004
Enrollment
50
Registered
2019-02-26
Start date
2018-06-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute asthmatic attack in emergency room rate of admission asthma attack acute exacerbation children asthma

Interventions

compair with NSS mixed with first dose salbutamol nebulization on acute asthmatic attack
Experimental Drug
budesonide 2000 mcg nebulization with first dose salbutamol

Sponsors

None listed

Eligibility

Sex/Gender
All
Age
No minimum to 15 Years

Inclusion criteria

Inclusion criteria: children diagnosed asthma or suspected asthama with acute asthmatic attack atER with any of asthma severety

Exclusion criteria

Exclusion criteria: BPD or chronic lung disease comorbid heart disease previously use systemic steroid in 7 days previously use high dose nebulized steroid for acut exacerbation before coming to the hospital

Design outcomes

Primary

MeasureTime frame
admission rate after resuscitation in ER number of patient admit

Secondary

MeasureTime frame
decrease in asthma score at 1 hr, 2 hr and befor discharge decrease in asthma score,readmission to ER from asthma exacerbation in 7 days number of patient

Countries

Thailand

Contacts

Public Contactkrongkwan Niemsorn

RAMATHIBODI HOSPITAL

krongkwan.ped@gmail.com66947494465

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026